Solid Tumor, Unspecified, Adult Clinical Trial
Official title:
Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.
This study will occur in two parts, Dose-escalation (Part 1) and Cohort-expansion (Part 2). The main purpose of Part 1 is to determine the doses and dosing schedule of MPB-1734 that is safe and tolerable when given in subjects with certain types of advanced cancer. Part 2 of the study will begin when the Sponsor determines the safe and tolerable doses and dosing schedule from Part 1. The main purpose of Part 2 is to continue to assess the safety and tolerability of the MPB-1734 dose and dosing schedule determined by the Sponsor during Part 1. The preliminary efficacy of MPB-1734 will also be assessed in both Part 1 and Part 2. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03628677 -
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05723640 -
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
|
Phase 1 | |
| Completed |
NCT04976803 -
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
|
||
| Recruiting |
NCT04932525 -
Gustave Roussy Cancer Profiling
|
Phase 1 | |
| Recruiting |
NCT04443088 -
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04942717 -
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
|
||
| Recruiting |
NCT04169321 -
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
|
Phase 1 | |
| Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
| Completed |
NCT03318445 -
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
|
Phase 1 | |
| Recruiting |
NCT04537936 -
Psychotherapy Intervention for Latinos With Adv Cancer
|
N/A | |
| Completed |
NCT04252339 -
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04577963 -
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06136065 -
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04015609 -
Psychotherapy Intervention for Latinos With Advanced Cancer
|
N/A | |
| Available |
NCT04100694 -
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
|